MAP2K7 and breast cancer: Moreover, the concentrations at which sorafenib inhibits FGFR1 autocrine activation in MPM TICs are similar to those reported to affect the RAF/MEK/ERK pathway and activated RTK in human breast cancer cell lines [48].